1. Home
  2. SANA vs VALN Comparison

SANA vs VALN Comparison

Compare SANA & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sana Biotechnology Inc.

SANA

Sana Biotechnology Inc.

HOLD

Current Price

$2.36

Market Cap

688.5M

Sector

Health Care

ML Signal

HOLD

Logo Valneva SE

VALN

Valneva SE

HOLD

Current Price

$5.41

Market Cap

582.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SANA
VALN
Founded
2018
2012
Country
United States
France
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
688.5M
582.2M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
SANA
VALN
Price
$2.36
$5.41
Analyst Decision
Strong Buy
Buy
Analyst Count
9
4
Target Price
$8.43
★ $12.25
AVG Volume (30 Days)
★ 2.9M
21.7K
Earning Date
11-09-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 17.24
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$87.65
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.22
$4.75
52 Week High
$5.63
$12.18

Technical Indicators

Market Signals
Indicator
SANA
VALN
Relative Strength Index (RSI) 32.63 39.94
Support Level $2.22 $5.10
Resistance Level $3.41 $5.52
Average True Range (ATR) 0.15 0.21
MACD 0.00 -0.02
Stochastic Oscillator 20.00 18.92

Price Performance

Historical Comparison
SANA
VALN

About SANA Sana Biotechnology Inc.

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Share on Social Networks: